Fibroblast growth factor receptor

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Retrieved on: 
Monday, October 26, 2020
Branches of biology, Tyrosine kinase receptors, Angiology, Medical specialties, Clusters of differentiation, Growth factors, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Angiogenesis inhibitor, Vascular endothelial growth factor, Angiogenesis

In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).

Key Points: 
  • In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).
  • The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.
  • Dr. Laurenz Kellenberger, Chief Scientific Officer, said: Our development strategy for derazantinib is focused on strengthening the evidence for its differentiation versus other FGFR inhibitors.
  • The preclinical data on derazantinibs anti-angiogenic activity presented at the conference show that it may provide additional activity on top of its established primary anti-tumor effects in FGFR-positive solid tumors.

Basilea reports data from poster presentations at ESMO Virtual Congress 2020

Retrieved on: 
Tuesday, September 22, 2020
Tyrosine kinase receptors, Branches of biology, Clusters of differentiation, Basilea Pharmaceutica, Cell biology, Fibroblast growth factor receptor 1, Biology, European Society for Medical Oncology, Fibroblast growth factor receptor, Fibroblast growth factor

Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) today reports on several e-posters with new preclinical and clinical data on its fibroblast growth factor receptor (FGFR) inhibitor derazantinib and its tumor checkpoint controller, lisavanbulin, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which took place from 19-21 September, 2020.
  • In addition, gastric and lung cancer models showed the strongest correlation of FGFR1-3 expression versus the anticancer activity of derazantinib.
  • The results support the planned clinical investigation of derazantinib in gastric cancer as its next indication.
  • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Intrahepatic Cholangiocarcinoma in China

Retrieved on: 
Thursday, September 3, 2020
Tyrosine kinase receptors, Branches of biology, Cancer, Health, Angiogenesis, Angiology, Organogenesis, Mesothelioma, Fibroblast growth factor receptor, C-Met

In normal physiology, FGF/FGFR signaling is involved in embryonic development (organogenesis and morphogenesis), tissue repair, angiogenesis, neuroendocrine and metabolism homeostasis.

Key Points: 
  • In normal physiology, FGF/FGFR signaling is involved in embryonic development (organogenesis and morphogenesis), tissue repair, angiogenesis, neuroendocrine and metabolism homeostasis.
  • Enrollment has been completed for the dose escalation of the Phase I study of HMPL-453 in China (clinicaltrials.gov identifier NCT03160833 ).
  • Enrollment of a Phase II study is ongoing in patients with advanced malignant mesothelioma in China (clinicaltrials.gov identifier NCT04290325 ).
  • For further discussion of these and other risks, see Chi-Meds filings with the U.S. Securities and Exchange Commission and on AIM.

Basilea announces data presentations at ESMO Virtual Congress 2020

Retrieved on: 
Tuesday, July 28, 2020
Branches of biology, Tyrosine kinase receptors, Basilea Pharmaceutica, Cell biology, ESMO, Fibroblast growth factor receptor, European Society for Medical Oncology, Oncology, Fibroblast growth factor, Biology

Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that three abstracts featuring preclinical and clinical data on its fibroblast growth factor receptor (FGFR) kinase inhibitor derazantinib and its tumor checkpoint controller lisavanbulin are going to be presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which is taking place from 19-21 September, 2020.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that three abstracts featuring preclinical and clinical data on its fibroblast growth factor receptor (FGFR) kinase inhibitor derazantinib and its tumor checkpoint controller lisavanbulin are going to be presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which is taking place from 19-21 September, 2020.
  • Dr. Marc Engelhardt, Chief Medical Officer, said: The preclinical derazantinib data may provide an explanation for differences in reported adverse event profiles between various FGFR kinase inhibitors.
  • He continued: We are also pleased that the full data from the phase 1 study with oral lisavanbulin in patients with recurrent glioblastoma will be presented at ESMO.
  • Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial for Achondroplasia

Retrieved on: 
Wednesday, July 15, 2020
Health, Genetics, Clinical trials, Research, Pharmaceutical, Science, Branches of biology, Growth disorders, Tyrosine kinase receptors, Rare diseases, Fibroblast growth factor receptor 3, Health, Medicine, Achondroplasia, Fibroblast growth factor receptor, Fibroblast growth factor, Hypochondroplasia, Achondroplasia in children, Phase 1 study, Achondroplasia

Achondroplasia has no known cure, and is designated as an intractable disease by the Ministry of Health, Labour and Welfare in Japan.

Key Points: 
  • Achondroplasia has no known cure, and is designated as an intractable disease by the Ministry of Health, Labour and Welfare in Japan.
  • This disease results mainly from a genetic variant in FGFR3 (fibroblast growth factor type 3 receptor).
  • Achondroplasia occurs in a frequency of 1 in approximately 25,000 normal live births and is estimated to affect approximately 250,000 people worldwide.
  • "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia

Retrieved on: 
Wednesday, July 15, 2020
Tyrosine kinase receptors, Rare diseases, Health, Growth disorders, Medicine, Medical specialties, Achondroplasia, RTT, Fibroblast growth factor receptor 3, Dose, Fibroblast growth factor receptor

Additionally, infigratinib is being studied as a once-daily dose taken orally, which is an important factor for administration of therapies to children with achondroplasia.

Key Points: 
  • Additionally, infigratinib is being studied as a once-daily dose taken orally, which is an important factor for administration of therapies to children with achondroplasia.
  • Our hope is that a daily, oral dose of infigratinib, which directly targets FGFR3, can provide health benefits for children with achondroplasia.
  • The PROPEL 2 trial is a Phase 2 dose escalation and dose expansion trial and the first clinical trial to study infigratinib at low doses in children with achondroplasia.
  • QED Therapeutics , an affiliate of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven diseases.

Taiho Oncology To Present Data on Futibatinib (TAS-120) at the AACR Annual Meeting 2020

Retrieved on: 
Thursday, June 4, 2020
Tyrosine kinase receptors, American Association for Cancer Research, Fibroblast growth factor receptor 1, TAS, Fibroblast growth factor receptor, AACR

PRINCETON, N.J., June 4, 2020 /PRNewswire/ --Taiho Oncology, Inc. today announced that preclinical data for futibatinib (TAS-120) will be presented online during the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 from June 22-24.

Key Points: 
  • PRINCETON, N.J., June 4, 2020 /PRNewswire/ --Taiho Oncology, Inc. today announced that preclinical data for futibatinib (TAS-120) will be presented online during the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 from June 22-24.
  • Key presentations include:
    Futibatinib (TAS-120) plus chemotherapy demonstrated a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models (Abstract 564).
  • Results will be shared online as a poster presentation on June 22, 2020.
  • The abstract for this presentation is available on the AACR website: https://www.abstractsonline.com/pp8/#!/9045/presentation/2469
    Synergistic antitumor activity of futibatinib (TAS-120), a FGFR1-4 inhibitor, and PI3K pathway inhibitors (Abstract 659).

GeneCentric Therapeutics to Present New Analyses of Molecular Characterization and Prediction of Treatment Response in Patients with Muscle Invasive Bladder Cancer (MIBC)

Retrieved on: 
Thursday, February 13, 2020
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Immune system, Branches of biology, Medicine, Organ systems, Programmed cell death protein 1, Checkpoint inhibitor, PD-L1, Immune checkpoint, Fibroblast growth factor receptor, Fibroblast growth factor

GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.

Key Points: 
  • GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.
  • The data are derived from GeneCentrics expertise in the identification of RNA-based Predictive Response Signatures and through collaborations with researchers at leading institutions and pharmaceutical companies.
  • The predictive value of fibroblast growth factor (FGFR) alterations on the treatment outcome of MIBC patients treated with immune checkpoint blockade (Anti-PD-L1/Anti-PD-1) was evaluated in the current analysis.
  • Details of the presentations are as follows:
    GeneCentric Therapeutics, Inc., based in Research Triangle Park, N.C., is an RNA-based genomic solutions provider.

Basilea reports positive preclinical data on oncology drug candidates derazantinib and lisavanbulin at AACR-NCI-EORTC conference

Retrieved on: 
Wednesday, October 30, 2019
Branches of biology, Tyrosine kinase receptors, Medical specialties, Medicine, Colony stimulating factor 1 receptor, European Organisation for Research and Treatment of Cancer, Basilea Pharmaceutica, Oncology, PD-1 and PD-L1 inhibitors, Macrophage colony-stimulating factor, PD-L1, Fibroblast growth factor receptor

Basel, Switzerland, October 30, 2019 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today presentations of supporting preclinical data, on its clinical stage oncology drug candidates derazantinib and lisavanbulin (BAL101553), at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA, on October 29, 2019.

Key Points: 
  • Basel, Switzerland, October 30, 2019 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today presentations of supporting preclinical data, on its clinical stage oncology drug candidates derazantinib and lisavanbulin (BAL101553), at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA, on October 29, 2019.
  • Dr. Marc Engelhardt, Basileas Chief Medical Officer, said: These late-breaking derazantinib data may have important clinical implications.
  • The data support the activity of derazantinib in urothelial cancer models with genetic FGFR aberrations and highlight the dual targeting of derazantinib through FGFR and CSF1R kinase inhibition.
  • The activity of derazantinib against CSF1R may increase the susceptibility of cancers to immunotherapy when derazantinib is combined with PD-1/PD-L1 inhibitors.

QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia

Retrieved on: 
Thursday, October 17, 2019
Tyrosine kinase receptors, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Achondroplasia, Branches of biology, Medical specialties, Medicine

SAN FRANCISCO, Oct. 17, 2019 /PRNewswire/ -- QED Therapeutics, Inc. and parent company BridgeBio Pharma, Inc. (NASDAQ: BBIO) announced today the presentation of preclinical data supporting the potential of low-dose infigratinib for the treatment of achondroplasia.

Key Points: 
  • SAN FRANCISCO, Oct. 17, 2019 /PRNewswire/ -- QED Therapeutics, Inc. and parent company BridgeBio Pharma, Inc. (NASDAQ: BBIO) announced today the presentation of preclinical data supporting the potential of low-dose infigratinib for the treatment of achondroplasia.
  • The preclinical study used a dwarf mouse model (Fgfr3Y367C/+), which mimics achondroplasia.
  • QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven diseases.
  • QED is also evaluating infigratinib in clinical studies for cancers driven by mutations in the FGFR1, 2, or 3 genes.